The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial rev...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Lanzi, Anastasia, Sinicrope, F. A., Benson, A. B., Galon, Jérôme
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2020
Témata:
Author's View
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7466859/
https://ncbi.nlm.nih.gov/pubmed/32934890
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1796003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky